Business
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global
About this update from Beyondspring, Inc.
[{"type":"text","content":"FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announces that it will have an oral presentation on the final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from Dublin-3 phase 3 study in EGFR wild-type 2L/3L non-small cell lung cancer (NSCLC) at the 2024 World Conference on Lung Cancer, on September 9, 2024 in San Diego, CA, and two poster presentations on Dublin-3 study safety outcome and 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) in 2L/3L NSCLC who failed PD-1/PD-L1 inhibitors at European Society for Medical Oncology (ESMO) Congress 2024, on September 14, 2024 in Barcelona, Spain. Presentation details are as follows: 2024 World Conference on Lung CancerOral (OA08.04): Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial Presenter: Dr. Trevor M. Feinstein, Principal investigator for Dublin-3 study, Piedmont Cancer Institute, Atlanta, GA, USAPresentation Time: Monday, September 9, 2024, at 10:57AM to 11:07AM PDTSession: OA08. The New Generation of Cytotoxics ESMO Congress 2024Poster (1358P): Plinabulin/Docetaxel Versus Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial Presenter: Dr. Trevor M. FeinsteinPresentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CESTLocation: Hall 3, Av. Joan Carles I, 64 08908 L’hospitalet de Llobregat Barcelona, Spain Session: NSCLC, metastatic Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization Presenter: Dr. Yan Xu, Investigator, Peking Union Medical College Hospital, Beijing, ChinaPresentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CESTLocation: Hall 3, Av. Joan Carles I, 64 08908 L’hospitalet de Llobregat Barcelona, Spain Session: NSCLC, metastatic About BeyondSpringBeyondSpring is a global clinical-stage biopharmaceutical ...